VEGFA and colorectal carcinoma: CO.20 was a negative randomized phase III trial comparing cetuximab plus placebo versus cetuximab and brivanib, a TKI targeting vascular endothelial growth factor and fibroblast growth factor, in metastatic, chemotherapy‐refractory, KRAS wild‐type CRC.8